Helixmith Co

Helixmith Co Liabilities

The The Liabilities of Helixmith Co (084990.KQ) as of Oct 25, 2026 is 1.67 B KRW. In the previous year, The Liabilities was 6.85 B KRW — a change of -75.58% (lower).

Liabilities

1.67 BKRW

YoY

-75.58%

Last updated:

In 2025, Helixmith Co's total liabilities amounted to 1.67 B KRW, a -75.58% difference from the 6.85 B KRW total liabilities in the previous year.

The Helixmith Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
150.37 B KRW
Jan 1, 2019
175.87 B KRW
Jan 1, 2020
201.84 B KRW
Jan 1, 2021
57.15 B KRW
Jan 1, 2022
37.26 B KRW
Jan 1, 2023
73.56 B KRW
Jan 1, 2024
6.85 B KRW
Jan 1, 2025
1.67 B KRW
The Helixmith Co Liabilities history
YEARLiabilitiesYoY
1.67 BKRW-75.58%
6.85 BKRW-90.68%
73.56 BKRW+97.41%
37.26 BKRW-34.80%
57.15 BKRW-71.68%
201.84 BKRW+14.76%
175.87 BKRW+16.96%
150.37 BKRW+907.27%
14.93 BKRW+110.01%
7.11 BKRW+108.25%
3.41 BKRW+3.28%
3.31 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Helixmith Co Stock analysis

What does Helixmith Co do? Helixmith Co., Ltd. generates revenue through its Natural Products Business segment, which develops and sells raw materials for functional materials and health functional foods under brands like Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment focuses on developing treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer therapies. Customers include companies in the health and pharmaceutical sectors seeking natural ingredients and specialized medical treatments. The company serves two distinct market segments: one for natural product raw materials and another for advanced biopharmaceutical solutions. The Natural Products Business segment targets clients requiring raw materials for functional materials and health functional foods, leveraging branded products Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment caters to healthcare providers and pharmaceutical firms developing treatments for specific medical conditions, including diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer applications. Both segments operate within the broader health and biotechnology industries, with the company's revenue streams derived from product sales across these specialized markets. Helixmith Co., Ltd. monetizes its research and development efforts through the commercialization of natural substance-based raw materials and biopharmaceutical treatments. The company's product portfolio includes Alex, Murphine, and Nimosin for the natural products market, while its biopharmaceutical segment offers treatments for diabetic neuropathy, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis, ischemic heart disease, and anticancer conditions. Revenue is generated from direct sales to businesses in the health, functional food, and pharmaceutical sectors, with no mention of additional revenue streams such as licensing or partnerships. Helixmith Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Helixmith Co's Liabilities

Helixmith Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Helixmith Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Helixmith Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Helixmith Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Helixmith Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Helixmith Co stock

The Liabilities of Helixmith Co is 1.67 B KRW in 2025.

The Liabilities of Helixmith Co changed from 6.85 B KRW to 1.67 B KRW, representing a -75.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Helixmith Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Helixmith Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Helixmith Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Helixmith Co